Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
5
POC Diagnostic for Gonorrhea and Determination of Antimicrobial Susceptibility
Award last edited on: 5/18/21
Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$300,000
Award Phase
1
Solicitation Topic Code
NIAID
Principal Investigator
Gary Schoolnik
Company Information
Visby Medical Inc
(
AKA
: Click Diagnostics)
3010 North First Street
San Jose, CA 95134
(833) 468-4729
info@visbymedical.com
www.visbymedical.com
Location:
Single
Congr. District:
17
County:
Santa Clara
Phase I
Contract Number:
75N93019C00019-0-9999-1
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2019
Phase I Amount
$300,000
Visby - formerlly known as Click Diagnostics - has developed a PCR based rapid disposable point of care test that automatically performs sample processing PCR amplification and amplicon detection Leveraging the existing platform Click will from a single urogenital sample detect NG and determine whether the infecting strain is susceptible to three classes of antibiotics ciprofloxacincefiximeor a novel antibiotic zoliflodacin. Because of the gonococci s ability to become resistant to almost every recommended antibioticonly one therapy is currently recommended by the CDC dual treatment with injectable ceftriaxone and oral azithromycin though reduced susceptibility has been observed for both By determining the genotype of the infecting strain WT gyrase A Serciprofloxacin susceptible or penA mosaic XXXIV reduced cefixime susceptibility we will be providing individualized treatment to patientsthus minimizing the use of ceftriaxone Additionally by detecting zoliflodacin resistant genotypes gyrase B DN KT SN we now have a companion diagnostic for this novel class of antibiotic. In Phase I Click has partnered with Dr Jeffrey Klausner UCLA to develop and test a multiplexed antimicrobial susceptibility assay to detect single nucleotide polymorphisms that confer susceptibility resistance to ciprofloxacincefixime and zoliflodacin. The new assay will retain similar specificity sensitivity PCR efficiency and limits of detection cfu mlas our current NG opaA assay
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.